Real Chemistry, a global AI and insights-driven healthcare communications firm, has announced the acquisition of Spurwing Communications, establishing the company’s first APAC strategic hub in Singapore.
“APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry, we’re expanding our presence in the region and deepening our ability to help clients drive measurable impact by delivering more connected, data-driven and culturally relevant engagement across these key markets.”
Founded in Singapore, Spurwing Communications has advised pharmaceutical and healthcare organisations, as well as clients across industries, throughout APAC. Emma Thompson, Founder and Chief Executive Officer (CEO) of Spurwing Communications, will continue to lead the business as President, APAC Growth, and will report to Kath.
“Joining Real Chemistry allows us to broaden what we can offer clients, while staying grounded in the strong regional expertise and senior counsel for which our clients value us,” said Emma. “I’m extremely proud of what we have achieved as a team and excited for the next phase of our growth as part of Real Chemistry. We will continue to support our existing clients while expanding our APAC presence and adding capabilities - including analytics and AI - to enhance our connected, comprehensive regional offerings.”
“Real Chemistry’s acquisition of Spurwing Communications is an important step in our global growth strategy,” said Shankar Narayanan, CEO of Real Chemistry. “We’re continuing to invest in the capabilities and regions that matter most to our clients as they navigate growing global commercialisation challenges. Strengthening our presence in APAC allows us to better support clients across the full lifecycle - from strategy through engagement - in one of the most dynamic healthcare markets in the world.”